The current dispute over Thailand and Brazil licensing generic versions of patented medicines severely tests global health and health-care-access policy. It also tests key US trade relations with Asia and the functionality of the global trade system itself. So far, the results aren’t encouraging, and meanwhile the issue is getting larger and more complex. Full Story
About OODA Analyst
OODA is comprised of a unique team of international experts capable of providing advanced intelligence and analysis, strategy and planning support, risk and threat management, training, decision support, crisis response, and security services to global corporations and governments.